{"disease":{"id":"venous-thromboembolic-disease","name":"Venous thromboembolic disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"xarelto","indication_name":"Venous thromboembolic disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rivaroxaban","indication_name":"Venous thromboembolic disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06232551","title":"Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":152000,"lead_sponsor_name":"Scott C. Woller, MD","has_results":false},{"nct_id":"NCT02425345","title":"Women's Health Initiative Strong and Healthy Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":49331,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04818151","title":"Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data","phase":"","overall_status":"COMPLETED","enrollment_count":14914,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT06855394","title":"Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13000,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT04211181","title":"CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":5800,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT04158973","title":"CHIPs-VTE Study in Hospitalized Patients With Lung Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3200,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT03206372","title":"Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure","phase":"","overall_status":"RECRUITING","enrollment_count":2640,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07016542","title":"Cohort for Monitoring Patients With Venous Thromboembolic Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT04007653","title":"Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT05396157","title":"Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":813,"lead_sponsor_name":"Mount Sinai Hospital, Canada","has_results":false},{"nct_id":"NCT02297373","title":"Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)","phase":"","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":true},{"nct_id":"NCT03937583","title":"Screening for Cancer in Patients With Unprovoked VTE","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":650,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT04846725","title":"Predictors of Attempted Inferior Vena Cava Filters Retrieval.","phase":"","overall_status":"COMPLETED","enrollment_count":356,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT03887806","title":"Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT02188056","title":"Observational Prospectif Monocentric Registry of Patients Suffering From VIE","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT04414332","title":"Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry","phase":"","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT03894878","title":"Association Between Genetic Variant Scores and Warfarin Effect","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Cipherome, Inc.","has_results":false},{"nct_id":"NCT05993533","title":"Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Direction Centrale du Service de Santé des Armées","has_results":false},{"nct_id":"NCT07270263","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Medical University of Gdansk","has_results":false},{"nct_id":"NCT04824118","title":"Clotting Parameters After Medical Abortion","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"NHS Lothian","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}